Pulmonary complications of solid organ and hematopoietic stem cell transplantation

被引:219
作者
Kotloff, RM
Ahya, VN
Crawford, SW
机构
[1] Univ Penn, Med Ctr, Sect Adv Lung Dis & Lung Transplantat, Pulm Allergy & Crit Care Div, Philadelphia, PA 19027 USA
[2] Naval Med Ctr, Div Pulm & Crit Care, San Diego, CA USA
关键词
hematopoietic stem cell transplantation; organ transplantation; pneumonia;
D O I
10.1164/rccm.200309-1322SO
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The ability to successfully transplant solid organs and hematopoietic stem cells represents one of the landmark medical achievements of the twentieth century. Solid organ transplantation has emerged as the standard of care for select patients with severe vital organ dysfunction and hematopoietic stem cell transplantation has become an important treatment option for patients with a wide spectrum of nonmalignant and malignant hematologic disorders, genetic disorders, and solid tumors. Although advances in surgical techniques, immunosuppressive management, and prophylaxis and treatment of infectious diseases have made long-term survival an achievable goal, transplant recipients remain at high risk for developing a myriad of serious and often life-threatening complications. Paramount among these are pulmonary complications, which arise as a consequence of the immunosuppressed status of the recipient as well as from such factors as the initial surgical insult of organ transplantation, the chemotherapy and radiation conditioning regimens that precede hematopoietic stem cell transplantation, and alloimmune mechanisms mediating host-versus-graft and graft-versus-host responses. As the population of transplant recipients continues to grow and as their care progressively shifts from the university hospital to the community setting, knowledge of the pulmonary complications of transplantation is increasingly germane to the contemporary practice of pulmonary medicine.
引用
收藏
页码:22 / 48
页数:27
相关论文
共 351 条
[61]   PREDICTIVE VALUE OF PULMONARY-FUNCTION TESTS BEFORE MARROW TRANSPLANTATION [J].
CRAWFORD, SW ;
FISHER, L .
CHEST, 1992, 101 (05) :1257-1264
[62]   LONG-TERM SURVIVAL FROM RESPIRATORY-FAILURE AFTER MARROW TRANSPLANTATION FOR MALIGNANCY [J].
CRAWFORD, SW ;
PETERSEN, FB .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (03) :510-514
[63]   ABNORMALITIES OF PULMONARY-FUNCTION TESTS AFTER MARROW TRANSPLANTATION PREDICT NONRELAPSE MORTALITY [J].
CRAWFORD, SW ;
PEPE, M ;
LIN, DY ;
BENEDETTI, F ;
DEEG, HJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (02) :690-695
[64]  
Crawford SW, 1998, NEW HORIZ-SCI PRACT, V6, P69
[65]   BIOPSY DIAGNOSIS AND CLINICAL OUTCOME OF PERSISTENT FOCAL PULMONARY-LESIONS AFTER MARROW TRANSPLANTATION [J].
CRAWFORD, SW ;
HACKMAN, RC ;
CLARK, JG .
TRANSPLANTATION, 1989, 48 (02) :266-271
[66]  
CURTIS DJ, 1995, BONE MARROW TRANSPL, V16, P169
[67]  
Curtis RE, 1999, BLOOD, V94, P2208
[68]  
DALESSANDRO AM, 1989, TRANSPLANT P, V21, P3560
[69]  
Date H, 1998, J HEART LUNG TRANSPL, V17, P869
[70]   Inhaled nitric oxide reduces human lung allograft dysfunction [J].
Date, H ;
Triantafillou, AN ;
Trulock, EP ;
Pohl, MS ;
Cooper, JD ;
Patterson, GA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (05) :913-919